Analysis Tools
mortality/aging
 |
• 9 of 17 mice treated with tamoxifen at 3 to 4 weeks of age die soon after treatment
• however, tamoxifen-tocixity is not responsible for observed deaths, 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age have a normal life span, and mice treated with tamoxifen from week 12 to 17 exhibit normal lethality
|
behavior/neurological
|
N |
• the surviving 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age exhibit normal behavior/neurological phenotypes
|
|
|
• at 12 weeks mice display low stance, inertia, tremor, arrhythmic breathing, splayed himdlimb and moderate hindlimb clasping
• during the last 4 weeks of life, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)
• mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms
|
|
|
• at 12 weeks, mice display moderate hindlimb clasping
• mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms
|
|
|
• at 12 weeks
• mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms
|
respiratory system
|
|
• at 12 weeks
• mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms
|
